The Rising Influence of Rising Affluence

[biocqr]

Yes. My Roth IRA and wife's retirement funds are 100% cash/mm. I'm holding 1 biotech in my trading account...KALA.

KALA is developing Eysuvis (loteprednol etabonate steroid) for dry eye disease. KALA had a previous CRL but with stricter inclusion criteria this current Ph 3 data looks approvable... p=0.0002 on the primary and p=.0007 on the secondary endpoints. Kala is expected to resubmit its NDA as a Class 2 resubmission in 2Q so expecting 4Q launch pending FDA approval. NVS needs to protect their Xiidra franchise so KALA is a good buyout candidate. AGN/ABBV also a possibility. Currently 400M mc with 200M cash.

KALA's latest presentation if interested...

http://investors.kalarx.com/presentations